Clinical · Molecular biology
Functional characterization of BRCA2 variants of uncertain significance identified in Korean breast cancer patients
Summary
This study functionally characterized three BRCA2 variants of uncertain significance (VUS) identified in Korean breast cancer patients. Using BRCA2-knockout cell lines and various functional assays, researchers evaluated sensitivity to DNA-damaging agents and homologous recombination efficiency. The p.Asp1990Ala variant exhibited a pathogenic-like functional phenotype, characterized by increased sensitivity to cisplatin, ionizing radiation, and olaparib, along with impaired homologous recombination repair. In contrast, the p.Gly1224Asp and p.Cys1820Tyr variants were found to be functionally neutral. These findings highlight the heterogeneity of BRCA2 VUS and the importance of functional assays for their clinical interpretation.
Critical appraisal
Clinical. This study has direct clinical implications for the management of breast cancer patients, especially in Asian populations where population-specific reference data are scarce. The functional characterization of the p.Asp1990Ala variant as pathogenic could justify a change in patient management, particularly guiding treatment towards targeted therapies such as PARP inhibitors (olaparib) for carriers of this variant. It could also influence family screening and prophylactic surgery decisions. Integrating these functional assays into VUS interpretation algorithms could improve diagnostic accuracy and access to personalized treatments, with a potential clinical impact in the medium term (3-5 years).
Molecular biology. The key discovery is the identification of the BRCA2 p.Asp1990Ala variant as having a pathogenic-like functional phenotype, characterized by increased sensitivity to cisplatin, ionizing radiation, and olaparib, along with a marked reduction in homologous recombination repair efficiency. The technologies employed include BRCA2-knockout cell lines (DLD-1) and a GFP-based reporter system to assess homologous recombination efficiency, complemented by cellular sensitivity assays. These methods provide robust analytical validity for evaluating the functional impact of variants. The validation of these VUS through functional assays provides essential complementary biological evidence for their classification, paving the way for more precise clinical tests to identify patients who may benefit from targeted therapies.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology